Primary cutaneous large cell lymphomas of follicular center cell origin

Willemze, Rein; Meijer, Chris J.L.M.; Sentis, Henri J.; Scheffer, E.; Vloten, W. A. van; Toonstra, Johan; Putte, S. C. J. van der

doi:10.1016/s0190-9622(87)70068-1

Cited by 174 publications

(97 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PCFCL must be distinguished from cutaneous DLBCL presenting on the leg, which is typically IRF4/MUM1+ and strongly BCL2+ and has a more unfavorable prognosis. 24,25 DLBCL: Some of the new categories of DLBCL are defined by extranodal primary sites and the association with viruses such as Epstein Barr virus (EBV) or HHV8. Two borderline categories have also been included for cases that cannot be distinguished between adult Burkitt's lymphoma and DLBCL, and primary mediastinal large B-cell lymphoma (PMBL) and nodular sclerosis classical Hodgkin lymphoma (NSCHL).…”

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

Non-Hodgkin’s Lymphomas

Ad¹,

Js²,

Rh³

et al. 2010

J Natl Compr Canc Netw

223

View full text Add to dashboard Cite

OverviewNon-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B-, T-, or natural killer (NK) lymphocytes. In the United States, B-cell lymphomas represent 80% to 85% of all cases, with 15% to 20% being T-cell lymphomas; NK lymphomas are very rare. In 2009, an estimated 65,980 new cases of NHL will be diagnosed and 19,500 will die of the disease.1 NHL is the sixth leading site of new cancer cases among men and fifth among women, accounting for 4% to 5% of new cancer cases and 3% to 4% of cancer-related deaths. Non-Hodgkin's Lymphomas Clinical Practice Guidelines in OncologyKey Words NCCN Clinical Practice Guidelines, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, mycosis fungoides, Sézary syndrome, marginal zone lymphoma, mucosaassociated lymphoid tissue lymphoma, diagnosis, treatment, hematopathology, immunohistochemistry, treatment guidelines, staging evaluation, lymphoma pathology (JNCCN 2010;8:288-334) NCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus. Category 2A: The recommendation is based on lowerlevel evidence and there is uniform NCCN consensus. Category 2B: The recommendation is based on lowerlevel evidence and there is nonuniform NCCN consensus (but no major disagreement). Category 3: The recommendation is based on any level of evidence but reflects major disagreement. Please NoteThese guidelines are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way.These guidelines are copyrighted by the National Comprehensive Cancer Network. All rights reserved. These guidelines and the illustrations herein may not be reproduced in any form without the express written permission of the NCCN © 2010. Disclosures for the NCCN Non-Hodgkin's Lymphomas Guidelines PanelAt the beginning of each NCCN guidelines panel meeting, panel members disclosed any financial support they have received from industry. Through 2008, this information was published in an aggregate statement in JNCCN and online. Furthering NCCN's commitment to public transparency, this disclosure process has now been expanded by listing all potential conflicts of interest respective to each individual expert panel member.Individual disclosures for the NCCN Non-Hodgkin's Lymphomas Guidelines Panel members can be found on page 334. (To view the most recent version of these guideli...

show abstract

Section: Primary Cutaneous Follicle Center Lymphomamentioning

confidence: 99%

Non-Hodgkin’s Lymphomas

Ad¹,

Js²,

Rh³

et al. 2010

J Natl Compr Canc Netw

223

View full text Add to dashboard Cite

show abstract

“…Primary cutaneous B-cell lymphomas (PCBCL) constitute approximately 20-25% of all cutaneous lymphomas and are defined as B-cell lymphomas originating in the skin with no evidence of extracutaneous disease at presentation and for at least 6 months after diagnosis [1][2][3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Cutaneous B‐cell lymphoma: Pathological spectrum and clinical outcome in 51 consecutive patients

Sah¹,

Barrans²,

Parapia³

et al. 2004

American J Hematol

View full text Add to dashboard Cite

The clinical behavior and optimal treatment of patients presenting with skin infiltration by B-cell lymphoma have not been established. To clarify this we assessed the clinical and laboratory features of 51 patients presenting with cutaneous infiltration by B-cell lymphoma. Follow-up data was available for 46 patients with a median age of 68 years (range 16-89 years) and a median follow-up of 32.5 months (range 5-123 months). Thirty-three of 51 (65%) patients had diffuse large B-cell lymphoma (DLBCL), and 15/51 (29%) had marginal zone lymphoma (MZL). The remaining 3 patients had follicular lymphoma, CLL, and post-transplant lymphoproliferative disease. Of the 33 patients with DLBCL, follow-up was available in 29; 24/29 (83%) had primary cutaneous disease, which was unifocal in 17/24 (71%). Following treatment, 8/24 (33%) of the primary cases relapsed. Of the 8 who relapsed, 7 had received local forms of treatment only. Follow-up data was available in 14/15 patients with MZL. 11/14 (79%) had primary cutaneous disease, which was unifocal in 8 (73%). Following treatment, 4 of these cases relapsed (36%); all had received local therapy only. It is evident from this study that a significant proportion (~20%) of patients who present with cutaneous infiltration by B-cell lymphoma have systemic disease. Staging is therefore mandatory in these patients. Approximately 1/3 patients with primary cutaneous DLBCL or MZL ultimately relapse, and relapse rates appear higher in thosepatients receiving local therapy only. Systemic or combined modality therapy may therefore be the most appropriate treatment at presentation. This should be assessed prospectively in randomized trials. Am.

show abstract

“…B-large cell lymphomas are mostly of follicle center cell origin and T-large cell lymphomas are classified according to the CD30 antigen expression which identify anaplastic large-cell lymphomas having a good prognosis. [3][4][5] Furthermore, these PCLL may have clinical behaviors and prognoses different from those of primary node-based malignant lymphomas of the same histologic subtype. 3,6 Treatment has not yet been well-defined, comprising radiotherapy, polychemotherapy or both, 7,8 and no prospective studies have been performed in this rare and heterogeneous group of patients.…”

Section: Introductionmentioning

confidence: 99%

Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas

et al. 1998

View full text Add to dashboard Cite

The objectives of this study were to evaluate the outcome after polychemotherapy for patients with primary cutaneous largecell lymphomas (PCLL) and to validate the recently proposed immunohistologic classification of cutaneous lymphomas. Among 140 patients with positive skin biopsies included in the LNH87 protocol (for treatment of aggressive lymphomas), 49 patients met the criteria of PCLL. Characteristics were: sex ratio M/F, 2.3; age 18 to 83 years (median, 52), peripheral lymph nodes, n = 22; diffuse disease, n = 12; median tumor size, 4.5 cm; elevated lactate dehydrogenase, n = 9; ECOG: 0/1, n = 49. Histology was: follicular center B cell, n = 23; B-lymphoblastic, n = 1; anaplastic large-cell lymphoma, n = 14 (T cell phenotype n = 8); CD30 ؊ T cell lymphoma, n = 11. All patients received polychemotherapy: under 70 years, ACVBP (three to four cycles and consolidation for 6 months) n = 25; mBACOD (eight cycles) n = 16; over 70 years, C(T)VP (six cycles) n = 8. Radiation therapy was not included in the protocol. With a median follow-up of 5 years, 24/49 patients had relapsed, with 20 skin relapses. Event-free (EFS) and overall survival (OS) at 5 years were, respectively, 50 and 77%. Significant adverse prognostic factors were: histology (CD30 ؊ T cell lymphoma) and diffuse cutaneous disease (Ͼ Ͼ Ͼ10% of skin). The presence of nodal involvement was only significant for EFS. When compared to 140 non-cutaneous lymphoma patients included in the same trial and fully matched for the main clinical characteristics, OS was similar. In conclusion, PCLL behaves like other localized B or T cell extranodal lymphomas with the same prognostic factors (LDH, ECOG, age) except for CD30 ؉ PCLL which have a very good prognosis.

show abstract

Primary cutaneous large cell lymphomas of follicular center cell origin

Cited by 174 publications

References 12 publications

Non-Hodgkin’s Lymphomas

Non-Hodgkin’s Lymphomas

Cutaneous B‐cell lymphoma: Pathological spectrum and clinical outcome in 51 consecutive patients

Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas

Contact Info

Product

Resources

About